Changes are detected in the EGFR targeted anticancer drug market, which Tagrisso dominated. Tagrisso sales stagnated for the first time due to sluggish primary treatment benefits. Leclaza, the only domestic new drug in the market, is threatening Tagrisso.

According to IQVIA, a pharmaceutical research institute, on the 5th, the size of the domestic EGFR TKI market last year was 156.4 billion won, up 2.8% from 152.1 billion won a year earlier. Compared to the growth trend so far, it has slowed down somewhat. The market surged from 55.4 billion won in 2017 to 104.3 billion won in 2018 and 132.2 billion won in 2019. Tagrisso's sales stood at 106.5 billion won last year, the same as the previous year. Tagrisso,